EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK and PROVIDENCE, R.I., June 12, 2018 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO)